GlassScriptPhysician profile
Edward M Jeryan
NPI 1053356295
$1,481.53
in general payments reported to CMS, 2019-2025
18 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $88.53 · 2021: $12.87 · 2022: $61.06 · 2023: $63.46 · 2024: $190 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.14 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $224.93 | 2019 | |
| Pfizer INC. | $176.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.41 | 2019 | |
| Ironwood Pharmaceuticals, INC | $115.64 | 2019 | |
| Exact Sciences Corporation | $97.33 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $88.53 | 2020 | |
| Glaxosmithkline, LLC. | $56.43 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Intuitive Surgical, INC. | $49.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.23 | 2019-2022 | |
| Lilly USA, LLC | $34.22 | 2021-2024 | Mounjaro |
| Sanofi Pasteur INC. | $31.03 | 2025 | |
| Seqirus USA INC | $24.95 | 2025 | Fluad, Flucelvax |
| Abbvie INC. | $19.95 | 2024 | |
| Tactile Systems Technology INC | $18.22 | 2024 | Flexitouch Plus, Entre Plus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.93 | 2023 | Seglentis |
| Smith+Nephew, INC. | $16.68 | 2024 | Collagenase Santyl |
| Otsuka America Pharmaceutical, INC. | $16.61 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Jeryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.